Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics

Psychiatric Services

Volumn 60, Issue 12, 2009, Pages 1686-1689

  Bell, Ryan C ^a   Farmer, Sharon ^b   Ries, Richard ^b   Srebnik, Debra ^b  

^a NEW YORK STATE OFFICE OF MENTAL HEALTH   (United States)

^b Child and Adolescent Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; CHOLESTEROL; CLOZAPINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAID; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 71549163794     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.12.1686     Document Type: Article

References (15)

1. Capasso R, Lineberry T, Bostwick J, et al: Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophrenia Research 98:287-294, 2008
2. Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry 64:1123-1131, 2007
3. Hennekens C, Hennekens A, Hollar D, et al: Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 150:1115-1121, 2005 (Pubitemid 41773510)
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
5. Newcomer J: Second-generation (atypical) antipsychotics and metabolic effects. CNS Drugs 19(suppl 1):1-93, 2005
6. Newcomer J: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Journal of Clinical Psychiatry 68(suppl 1):20-27, 2007
7. McEvoy J, Meyer J, Goff D, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80:19-32, 2005 (Pubitemid 41587460)
8. Van Winkel R, De Hert M, Van Eyck D, et al: Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. Journal of Clinical Psychiatry 67:1493-1499, 2006
9. Mackin D, Bishop D, Watkinson H, et al: Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry 191:23-29, 2007
10. Kilbourne A, Brar J, Drayer R, et al: Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective, and bipolar disorder. Psychosomatics 48:412-417, 2007 (Pubitemid 47330294)
11. Spelman LM, Walsh PI, Sharifi N, et al: Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabetic Medicine 2:481-485, 2007
12. Ogden CL, Carroll MD, et al: Obesity Among Adults in the United States: No Change Since 2003-2004. NCHS Data Brief No 1. Hyattsville, Md, National Center for Health Statistics, 2007
13. National Heart, Lung, and Blood Institute: Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md, National Institutes of Health, 2004
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 31(suppl 1):S55-S60, 2008
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421, 2002